The FDA on June 29, 2020 approved KEYTRUDA® for the first-line treatment of patients with unresectable or metastatic MicroSatellite Instability-High (MSI-H) or MisMatch Repair deficient (dMMR) Colorectal cancer. KEYTRUDA® is a product of Merck & Co.
Bottom Ad
Advertisement
Subscribe
